Plasma Eicosanoids Characterized During Gestation Predicts Outcome
|
By LabMedica International staff writers Posted on 03 Sep 2020 |

Image: The UltiMate 3000 RS HPLC system and mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Fetal growth disorders are major risk factors for adverse pregnancy and later life outcomes. Proxy outcomes for disorders of fetal growth include small for gestational age (SGA) and large for gestational age (LGA) birth weight. Risk factors for SGA include maternal obstetrical complications, fetal genetic factors, infection, and various medical conditions.
Eicosanoids, an important class of lipid mediators derived from polyunsaturated fatty acids, can act as both direct influences and biomarkers of inflammation through a variety of biological pathways. Eicosanoids produced from the oxygenation of polyunsaturated fatty acid precursors, including the primary omega-6 fatty acids (linoleic acid [LA] and arachidonic acid [AA]) and omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid.
Scientists from the National Institute of Environmental Health Sciences (Research Triangle, NC, USA) and their colleagues carried out a case–control study of 90 pregnant women within a cohort study that included 31 women who delivered small for gestational age (SGA) babies (SGA, ≤10th percentile), 28 who delivered large for gestational age (LGA) babies (≥90th percentile), and 31 who delivered appropriate for gestational age (AGA) babies (controls, >10th to <90th percentile).
A panel of eicosanoids and fatty acids was measured in plasma samples by the mass spectrometry. Non-esterified (free) eicosanoid and fatty acid levels were quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Online liquid chromatography and electrospray ionization tandem mass spectrometry of extracted plasma samples were performed on an UltiMate 3000 RS HPLC system and Quantiva mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). For statistical analyses, they examined eicosanoids that were detected in ≥50% of all plasma samples analyzed. A total of 27 eicosanoids met this criterion while the other 30 were excluded.
The scientists reported that maternal plasma levels of eicosanoids and fatty acids generally followed U-shaped curve patterns across gestation. Bayesian models showed that associations between eicosanoids and case status varied by biosynthetic pathway. Eicosanoids derived from AA via the cytochrome P450 (CYP) and lipoxygenase (LOX) biosynthetic pathways were positively associated with SGA. The adjusted mean concentration of 12-Hydroxyeicosatetraenoic acid (12-HETE), a LOX pathway product, was 56.2% higher among SGA cases compared to AGA controls. Eicosanoid associations with LGA were mostly null, but negative associations were observed with eicosanoids derived from AA by LOX enzymes. The fatty acid precursors had estimated mean concentrations 41%–97% higher among SGA cases and 33%–39% lower among LGA cases compared to controls.
The authors concluded that eicosanoids and fatty acids systematically change in maternal plasma over pregnancy. Eicosanoids from specific inflammation-related pathways were higher in mothers of SGA cases and mostly similar in mothers of LGA cases compared to controls. These findings can provide deeper insight into etiologic mechanisms of abnormal fetal growth outcomes. The study was published on August 14, 2020 in the journal PLOS Medicine.
Eicosanoids, an important class of lipid mediators derived from polyunsaturated fatty acids, can act as both direct influences and biomarkers of inflammation through a variety of biological pathways. Eicosanoids produced from the oxygenation of polyunsaturated fatty acid precursors, including the primary omega-6 fatty acids (linoleic acid [LA] and arachidonic acid [AA]) and omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid.
Scientists from the National Institute of Environmental Health Sciences (Research Triangle, NC, USA) and their colleagues carried out a case–control study of 90 pregnant women within a cohort study that included 31 women who delivered small for gestational age (SGA) babies (SGA, ≤10th percentile), 28 who delivered large for gestational age (LGA) babies (≥90th percentile), and 31 who delivered appropriate for gestational age (AGA) babies (controls, >10th to <90th percentile).
A panel of eicosanoids and fatty acids was measured in plasma samples by the mass spectrometry. Non-esterified (free) eicosanoid and fatty acid levels were quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Online liquid chromatography and electrospray ionization tandem mass spectrometry of extracted plasma samples were performed on an UltiMate 3000 RS HPLC system and Quantiva mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). For statistical analyses, they examined eicosanoids that were detected in ≥50% of all plasma samples analyzed. A total of 27 eicosanoids met this criterion while the other 30 were excluded.
The scientists reported that maternal plasma levels of eicosanoids and fatty acids generally followed U-shaped curve patterns across gestation. Bayesian models showed that associations between eicosanoids and case status varied by biosynthetic pathway. Eicosanoids derived from AA via the cytochrome P450 (CYP) and lipoxygenase (LOX) biosynthetic pathways were positively associated with SGA. The adjusted mean concentration of 12-Hydroxyeicosatetraenoic acid (12-HETE), a LOX pathway product, was 56.2% higher among SGA cases compared to AGA controls. Eicosanoid associations with LGA were mostly null, but negative associations were observed with eicosanoids derived from AA by LOX enzymes. The fatty acid precursors had estimated mean concentrations 41%–97% higher among SGA cases and 33%–39% lower among LGA cases compared to controls.
The authors concluded that eicosanoids and fatty acids systematically change in maternal plasma over pregnancy. Eicosanoids from specific inflammation-related pathways were higher in mothers of SGA cases and mostly similar in mothers of LGA cases compared to controls. These findings can provide deeper insight into etiologic mechanisms of abnormal fetal growth outcomes. The study was published on August 14, 2020 in the journal PLOS Medicine.
Latest Clinical Chem. News
- Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
Channels
Molecular Diagnostics
view channel
Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
Lung cancer screening can detect stage 1 disease, but false-positive findings, repeated follow-up, and radiation exposure remain important concerns. Current NHS screening is limited to current and former... Read more
FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
Influenza and respiratory syncytial virus (RSV) often circulate during the same season and cause overlapping symptoms, making accurate differentiation important for clinical management. Seasonal testing... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







